Xeris Biopharma Holdings Inc (STU:2B30)

€ 3.302 0.14 (4.43%) Market Cap: 490.65 Mil Enterprise Value: 684.05 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 70/100

Q3 2024 Xeris Biopharma Holdings Inc Earnings Call Transcript
Nov 08, 2024

€3.17 (+3.80%)

Earnings
Q2 2024 Xeris Biopharma Holdings Inc Earnings Call Transcript
Aug 08, 2024

€1.91 (-0.05%)

Earnings
Q4 2023 Xeris Biopharma Holdings Inc Earnings Call Transcript
Mar 06, 2024

€2.58 (-7.19%)

Earnings
Xeris Biopharma Holdings Inc at JPMorgan Healthcare Conference Transcript
Jan 11, 2024
Q3 2023 Xeris Biopharma Holdings Inc Earnings Call Transcript
Nov 09, 2023

€1.97 (+9.44%)

Earnings
Q2 2023 Xeris Biopharma Holdings Inc Earnings Call Transcript
Aug 08, 2023

€2.24 (-4.27%)

Earnings
Q1 2023 Xeris Biopharma Holdings Inc Earnings Call Transcript
May 09, 2023

€2.42 (+12.04%)

Earnings
Q4 2022 Xeris Biopharma Holdings Inc Earnings Call Transcript
Mar 08, 2023

€1.42 (+5.97%)

Earnings
Xeris Biopharma Holdings Inc at JPMorgan Healthcare Conference Transcript
Jan 12, 2023
Q3 2022 Xeris Biopharma Holdings Inc Earnings Call Transcript
Nov 09, 2022

€1.53 (+2.33%)

Earnings
Xeris Biopharma Holdings Inc XP-8121 Call Transcript
Oct 20, 2022
Q2 2022 Xeris Biopharma Holdings Inc Earnings Call Transcript
Aug 10, 2022

€1.64 (-7.76%)

Earnings
Q1 2022 Xeris Biopharma Holdings Inc Earnings Call Transcript
May 11, 2022

€1.67 (-3.42%)

Earnings
Q4 2021 Xeris Biopharma Holdings Inc Earnings Call Transcript
Mar 10, 2022

€2.3 (+5.50%)

Earnings
Q3 2021 Xeris Biopharma Holdings Inc Earnings Call Transcript
Nov 10, 2021

€1.64 (-2.03%)

Earnings

Xeris Biopharma Holdings Inc XP-8121 Call Transcript

Oct 20, 2022 / 12:30PM GMT

Release Date Price: €1.25 (-6.46%)

Transcript

Operator

Good morning, everyone, and welcome to today's Top Line Phase I Study Results of XP-8121. My name is Drew, and I'll be coordinating your call today. (Operator Instructions). I'm now going to hand over to Allison Wey, Senior Vice President, Investor Relations and Corporate Communications, to begin. Please go ahead.

Allison Wey

Xeris Biopharma Holdings, Inc. - SVP of IR & Corporate Communications

Thank you, Drew. Good morning and thank you for joining us to discuss the results of our Phase I study of XP-8121. A press release was issued earlier this morning and can be found on our website. We are joined today by Paul Edick, Chairman and CEO; and Ken Johnson, Senior Vice President of Global Development and Medical Affairs. Paul will provide opening remarks, and Ken will review the study design and results, and then we'll open the line for questions.

Before we begin, I would like to remind you that this call will contain forward-looking statements concerning Xeris' business practices, Xeris' future expectations, plans, prospects, clinical approvals,

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.